Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients.
J Antimicrob Chemother
; 79(5): 1196-1200, 2024 05 02.
Article
in En
| MEDLINE
| ID: mdl-38538154
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Adenosine
/
Adenosine Monophosphate
/
Immunocompromised Host
/
Alanine
/
Drug Therapy, Combination
/
SARS-CoV-2
/
COVID-19 Drug Treatment
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
J Antimicrob Chemother
Year:
2024
Document type:
Article
Affiliation country:
Taiwán
Country of publication:
Reino Unido